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1. Introduction
Leishmaniasis is a chronic disease affecting the skin, mucosal and/or internal organs, caused
by flagellate protozoa Leishmania of the Trypanosomatidae family. [1] It is among the six most
important disease in terms of its impact in public health. The world incidence of leishmaniasis
is very large with about half a million new cases per year. About 12 million people are infected
with Leishmania ssp parasites worldwide. New treatment alternatives are highly needed. Our
goal here is to critically revise the literature in order to show the potential of Photodynamic
Therapy in the treatment and comprehensive control of this disease. We have separated this
chapter in nine sections, besides this brief introduction, which are: Leishmaniasis: Background
and treatment strategies; Mechanisms in Photodynamic Therapy; Treatment of animals
infected with leishmaniasis using PDT; Vector control using PDT; PDT alternatives for Blood
purification; PDT on the treatment of Old World Tegumentary Leishmaniasis; PDT - In vitro
tests in species that cause Tegumentary Leishmaniasis; Conclusions; References.
2. Leishmaniasis — Background and treatment strategies
There are two main forms of leishmaniasis, visceral (VL) and tegumentary (TL) leishmaniasis,
which are also respectively called Kala Azar and Bauru ulcer. The later, received its name
because of the original high prevalence in Bauru, a city in the countryside of the State of São
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Paulo, in Brazil. The tegumentary leishmaniasis is characterized by skin lesions (cutaneous-
CL) and mucocutaneous lesions (such as, nasal and mouth regions) [2].
Leishmaniasis is a common zoonosis, with domestic (dogs and cats) and wild (rodents,
marsupials, edentulous and wild canids) reservoirs. It is transmitted to humans by sand flies,
which comprise the genus Lutzomyia and Phlebotomus. Details of the etiology and patho‐
physiology of the disease are out of the scope of this chapter and we suggest that the reader
consult reviews that focus on these subjects [3].
The current scenario of leishmaniasis treatment is not promising. Therapeutic approaches
include systemic administrations of anti-parasitic medications, which often present serious
side effects. Few drugs are available in the clinic, mainly antimonials and amphotericin, and
the frequency of resistance development is rising. Therefore, there is an urgent need to establish
new and more effective treatments for both VL and TL. The treatment of TL (the focus of this
chapter) urges new drugs and new therapeutic forms, that allows for more effective and
conveniently administered treatments [4].
One of the promising approaches, and the one discussed in here, is photodynamic therapy
(PDT). The main expectation of this approach is that it treats lesions in a localized manner,
without damaging healthy tissues [5]. The few reports that are available in the literature have
validated this hypothesis. In addition, no sign of systemic toxicity is reported in PDT, elimi‐
nating one of the major health issues related to existing TL treatments.[6] These points will be
further discussed in this chapter.
The use of light as a therapeutic modality has gained strong impulse recently due to the
development of efficient and affordable light sources. Consequently, photo-activated drugs
(PhotoSensitizers-PS) play key roles in the present clinical portfolio, and more importantly,
are the major lead in the development of new drugs to treat a variety of diseases such as cancer,
microbial infections and tropical diseases. However, increasing the efficiency of PDT photo‐
sensitizers remains challenging [7-9].
The use of PDT in veterinary is much less common even considering the benefits that such
strategies could bring in the treatment of high-value reproducing animals, as well as, in the
treatment of animals that are reservoirs of human diseases [10].
In terms of developing effective treatments against leishmaniasis in endemic areas, it is
important to think of comprehensive strategies that could cause a quick decrease in the pool
of infected patients (Figure 1). It is also important to emphasize that leishmaniasis is a neglected
tropical disease and, therefore, it is highly relevant to consider low-cost strategies that would
serve as an alternative for public medicine in poor countries [9]. Developing efficient clinical
protocols that would cure/control the disease would not only favor the patient itself, but also,
would decrease the chance of this infection being transmitted to others by the vectors or by
blood transfusion. In the next sections, we will explain how PDT can be helpful in the treatment
of patients, as well as, of all the possible reservoirs and transmitting vectors that would favor
the parasite infection cycle (Figure 1). Some of this potential has been attained and some are
still in the step of hypothesis testing.
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